MeiraGTx Holdings plc · Biotech

MGTX

Elevated riskNext report: Around Nov 12 (est.)

View price ↗

The short version

A company still losing money with growing sales, with high risk. Institutions are adding.

Going well

Sales up 145% last year

Watch out for

About 17 months of cash left at its current burn
Owes more than it owns (negative equity)
Share count growing 21.2% a year (dilution)

Money moves

Insiders sold $851K in the last 30 days, all through pre-planned sales
Institutions added 17% to their holdings in the quarter ending June 2026 (119 bought, 34 sold)

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$9.190.0% that day

Company value: $883M; Share price times all shares
Price vs profit (P/E): 12.9x; You pay about $13 for each $1 of yearly profit
Price vs sales: 2.2x; Company value is 2.2 times a year of sales
Cash vs value: 16%; Cash as a share of company value
Debt vs value: 6%; Debt as a share of company value

From MGTX's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$321.4M

Sep '23Tap a barJun '26

Last 12 months: $397.5M. Over 5 years, sales grew about 39% a year.

What the price assumes

Your guesses, our math

Move the sliders to your own view of MGTX. Starting points are the company's recent numbers.

Sales growth+30% a yearRecently: +39% a yearProfit margin20%Last 12 months: 19.9%P/E at the end13xToday: 12.9x. Many steady companies trade at 12x to 25xShare count change+10% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$1.5B

Profit in 5 years$295M

Price these guesses point to$24.81+170% vs $9.19 todayAbout +22% a year, before dividends

What today's price needs: with a 20% margin and a 13x P/E, sales would have to grow about 6.6% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

0/5Weak

MissDebt under half of equityNot relying on borrowed money.Owes more than it owns
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-140.3%
MissProfitable every yearSteady profits, not one good year.0 of 9 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$50.2M
MissShare count not growingNot diluting owners. Falling means buybacks.+78.0% in 3 years

Revenue: $81.4M; +144.6% vs prior year
5-year growth: +39.2%/yr; revenue, per year
Total debt: $49.7M
Current ratio: 0.75x; short-term assets / bills due

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 13

Revenue: $321.4M; +8608.6% YoY
EPS: $1.71; vs -$0.48
Op. margin: 76.0%; +1289.6 pts
Free cash flow: -$38.9M
Share count: +16.4%; vs a year ago

Insider rating

Last 90 days

45Mixed

Pre-planned sales of $851K (weaker signal)

50 is neutral. Buying by more insiders, top executives and bigger stakes raises it. Selling lowers it; pre-planned sales count less.

Weekly insider trend

13 weeks agoBoughtSoldThis week

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 1.0
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+16.7%

Institutions added 16.7% to their holdings. 119 bought, 34 sold. 3 quarters of net buying in a row.

Shares held by institutions79.2M

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+17.2%

Cash runwayAt last year's cash burn

37 months

Debt to equityLatest balance sheet: debt compared with what owners have

Owes more than it owns

Shares outstandingLatest reported

96M

Why elevated risk

Losing money, losses are large next to sales
Share count growing 17.2% a year (dilution)
1 offering filing in 6 months (may sell new shares)

Earnings reports

Last 12

Next reportAround Nov 12 (est.)Estimated from the same quarter last year

Results filedAug 13
Results filedMay 14
Results filedMar 26
Results filedNov 13, 2025
Results filedAug 14, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

5%+ holder update (passive)Aug 14 · View filing ↗Big holder Major agreementJul 7 · View filing ↗Offering

Insider trades

Open-market buys and sells, last 90 days

Bought$00 insiders

Sold$851K2 insiders, 2 pre-planned

Insider	Trade	Shares	Avg price	Value	Owns after	Date
Richard GirouxCFO & COO	Sell	56K	$9.95	$557K	853K	Oct 20Filing ↗
-6.2% of their holdings Pre-planned sale (10b5-1) Filed same day
Stuart NaylorCHIEF SCI OFCR, OPHTHALMOLOGY	Sell	28K	$10.64	$294K	613K	Oct 6Filing ↗
-4.3% of their holdings Pre-planned sale (10b5-1) Filed same day